Actively Recruiting
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
Led by M.D. Anderson Cancer Center · Updated on 2026-02-25
36
Participants Needed
1
Research Sites
311 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical research study is to learn about the safety and effects of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss.
CONDITIONS
Official Title
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histologically confirmed advanced or metastatic solid tumor refractory to or not eligible for standard therapy
- Homozygous deletion of MTAP confirmed by certified testing
- Archived tumor tissue available or agreement to pre-treatment biopsy for Part A
- Ability and willingness to sign informed consent
- Ability to comply with study protocol
- ECOG performance status of 0 or 1
- Life expectancy of at least 3 months
- Measurable or evaluable disease as per RECIST v1.1 criteria
- Adequate washout from prior therapies before starting study treatment
- Recovery from prior therapy toxicities to Grade 1 or less except alopecia and peripheral neuropathy
- Adequate organ and marrow function within 28 days prior to treatment
- Ability to take oral medications
- Women of childbearing potential must have negative pregnancy test and agree to use effective contraception during and 6 months after treatment
You will not qualify if you...
- Prior treatment with PRMT5 or methionine adenosyltransferase 2A inhibitors (Part B only)
- Known additional progressing malignancy requiring active treatment except certain skin and cervical cancers
- Meningeal carcinomatosis, spinal cord compression, or symptomatic/unstable brain metastases
- Use of strong CYP3A inhibitors or inducers within 14 days before and during study treatment
- Clinically significant uncontrolled comorbidities including cardiac or pulmonary diseases
- Treatment with live attenuated vaccine within 4 weeks prior to treatment
- Use of medications that are sensitive substrates of breast cancer resistance protein or P-glycoprotein
- Pregnancy, breastfeeding, or planned conception during study and for 7 months after last dose
- Psychiatric or substance abuse disorders interfering with study cooperation
- Concurrent use of other investigational agents
- History of allergic reactions to similar compounds
- Active infection requiring intravenous antibiotics
- Gastrointestinal disorders significantly affecting drug absorption
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
J
Jordi Rodon Ahnert, MD, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here